Ascletis pursues oral IL-17A inhibitor for psoriasis as Invivyd readies COVID-19 filing
Ascletis, a biotech listed in Hong Kong, is developing a small‑molecule IL-17A inhibitor in pill form to treat psoriasis. The company aims to challenge the current injectable therapies that target the same pathway.
The oral formulation is intended to provide a more convenient option for patients who currently receive injectable biologics, potentially expanding market access for IL-17A targeting treatments.
In a separate update, Invivyd announced plans to submit a regulatory filing for a product related to COVID-19, indicating progress toward market authorization.
The briefing also referenced additional news items involving Breye, Immix and Aptadir, though no further details were provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that